The one aspect that is left out in considering risk vs benefit with these studies:
http://www.oncolink.org/resources/ar...h=01&year=2002
"We're talking about subtle differences; we're not talking about impaired or disabled women. And we do not want to say that adjuvant agents are not worthwhile; they are life-saving and appropriate in many cases," Dr. Ganz told Reuters Health.
However, she added, for women with very small tumors (no more than 1 cm) who may not be at risk for recurrence, adjuvant therapy "may contribute to some subtle decline in functioning."
The issue she is most likely to counsel these patients about is poorer sexual functioning. "The patient at least needs be forewarned that this might happen."
J Natl Cancer Inst 2002;94:39-49.